uniQure recently announced new data from its phase 3 HOPE-B trial of etranacogene dezaparvovec, the company’s investigational gene therapy candidate for patients with severe and moderately severe hemophilia B. The therapy consists of an adeno-…
Medscape has launched the latest educational activity in their “Clinical Advances in Gene Therapy for Hemophilia” series, which is presented through a collaboration between Medscape and the National Hemophilia Foundation. “Updates on Gene…
Pfizer recently announced that the first participant has been dosed in the phase 3 BASIS study of marstacimab, the company’s investigational hemophilia therapy that targets an anticoagulant protein known as tissue factor pathway inhibitor (TFPI…
GlossaryAIDS (acquired immunodeficiency syndrome)—a disease caused by the human immunodeficiency virus (HIV), which attacks the body’s immune system, making it more prone to certain infections and rare cancers.anemia…
We invite you to join the quarterly board of directors meeting for the National Hemophilia Foundation on Thursday, December 3rd at 7:00 PM EDT. This meeting will discuss NHF business operations and decisions and is…
BCS Financial (BCS), a market leading insurer and reinsurer today announced its partnership with the National Hemophilia Foundation (NHF), bringing to market a solution set for health plans and their members to improve the quality and cost of care…
In the second half of 2020, President Trump released several executive orders (EO) related to drug pricing. EOs describe broad policy goals that then are implemented via regulation or guidance by a given agency. That means that implementation of…